To the Editors:
===============

In their recent publication, Grindeland et al^[@R1]^ raised an important question of whether respiratory syncytial virus (RSV) hospitalizations increased following decreased use of RSV immunoprophylaxis among high-risk infants and children. The authors appropriately state that their analysis of 34,000 children \<24 months of age provided 80% power to detect an increase from 5 to 7.5 RSV hospitalizations per 1000 children. However, the authors did not address whether an increase of that magnitude could have been caused by the decreased use of RSV immunoprophylaxis.

The 2014 American Academy of Pediatrics Committee on Infectious Diseases guidance recommended stopping the use of RSV immunoprophylaxis among infants who are born at 29--31 weeks gestation and are \<6 months of age at RSV season start, infants who are born at 32--34 weeks gestation and are \<90 days of age during the RSV season with preschool-aged siblings or daycare attendance and children with hemodynamically significant congenital heart disease who are 12--23 months of age at RSV season start. Based on Centers for Disease Control natality statistics regarding the incidence of preterm births and published estimates of the prevalence of hemodynamically significant congenital heart disease among children 12--23 months of age, these aforementioned populations cumulatively represent approximately 0.77% of US children \<24 months of age (Table [1](#T1){ref-type="table"}).^[@R2]--[@R5]^
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To increase the RSV hospitalization rate among all children \<24 months of age by 2.5/1000, the 0.77% of children who were affected by the guidance would have to experience an absolute increase of 323 RSV hospitalizations per 1000. With RSV immunoprophylaxis efficacy of 45%--80%,^[@R6]^ this increase would require a total RSV hospitalization incidence in the absence of RSV immunoprophylaxis of 404--718/1000.

Incidence rates of this magnitude exceed those ever observed in any high-risk population, demonstrating that the study by Grindeland et al did not have sufficient statistical power to detect a clinically plausible increase in RSV hospitalizations following adoption of the 2014 Committee on Infectious Diseases guidance.
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